Dongtian Changchun ointment for moderate-to-severe chronic obstructive pulmonary disease: a multicenter, prospective, open-label, randomized controlled trial.
DTCO significantly reduced the frequency and duration of AECOPD in patients with moderate-to-severe COPD, and demonstrated satisfactory safety.
Authors
- Shanqun Li (ORCID: https://orcid.org/0000-0002-8096-9780)
- Yibao Zhang (ORCID: https://orcid.org/0000-0003-3658-0687)
- Wei Zhang (ORCID: https://orcid.org/0000-0003-4816-8390)
- Feng Chen (ORCID: https://orcid.org/0000-0003-3508-8834)
- Wei Jia (ORCID: https://orcid.org/0000-0002-3739-8994)
- Zhenwei Wang (ORCID: https://orcid.org/0000-0001-9552-0356)
- Wenjie Lu (ORCID: https://orcid.org/0009-0005-5022-6758)
- Meng Sun (ORCID: https://orcid.org/0000-0001-8631-4788)
- Yufang Bao
- Tang Binqing
- Qian Yechang
Institutions
- Fudan University (CN)
- Shanghai Stomatological Hospital (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Integrated Chinese Medicine (China) (HK)
- Longhua Hospital Shanghai University of Traditional Chinese Medicine (CN)
- Zhongshan Hospital (CN)
- Pudong Medical Center (CN)
- Yueyang Hospital (CN)
- Shanghai Traditional Chinese Medicine Hospital (CN)
- Shuguang Hospital (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-12-01
- DOI
- https://doi.org/10.19852/j.cnki.jtcm.2025.06.017
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00